Strategies for Infection Control in Cystic Fibrosis

Slides:

Advertisements

Similar presentations

The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis S. Sciuca 1,2, L. Balanetchi.

Advertisements

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.

Brief History in USA & UK

Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;

Pseudomonas Infection in Cystic Fibrosis

Talking to Patients About HCV Treatment

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Improving the Diagnosis and Treatment of Seizures in Long-term Care

Cost of care and clinical condition in paediatric cystic fibrosis patients Ulrich Baumann, Christiane Stocklossa, Wolfgang Greiner, Johann-Matthias Graf.

Pseudomonas Lung Infections in Cystic Fibrosis

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

New Directions in iTTP.

Optimizing HIV Care By Guiding and Educating the Workforce

Patient-Centered Care in Cystic Fibrosis

Ending HCV: How Do We Get There From Here?

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Advances in Cystic Fibrosis Views and Perspectives From Basel, Switzerland, 2016.

Infections in Patients with Cystic Fibrosis

HBV Care Models: Community Collaborations for Best Practices

Combination Inhaled Therapy in COPD: The Impact of Recent Data

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Advances in Cystic Fibrosis Perspectives From Orlando, 2016

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

Seizures in the Elderly: Treatment and Special Considerations

Initiating Pre-exposure Prophylaxis The PrEP Checklist

Poor Response to Initial Therapy for Migraine

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Tools to Address Adherence Issues in Patients With SIHD

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Program Goals Overview Is NEDA a Reasonable Target?

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

D. Worlitzsch, C. Rintelen, K. Böhm, B. Wollschläger, N. Merkel, M

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Managing Age-Related Clinical Issues in Hemophilia

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

Program Goals Disclaimers Defining Refractory Seizures.

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

A. Oliver, A. Mena Clinical Microbiology and Infection

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Addressing Treatment Challenges in Cystic Fibrosis

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

UK Cystic Fibrosis Registry Annual Data Report 2017

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates G.A. Tramper-Stranders,

A specific database for providing local and national level of integration of clinical data in cystic fibrosis T. Leal, G. Reychler, P. Mailleux, J. Gigi,

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Eradication of early P. aeruginosa infection in children

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi,

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Gamma camera scans showing posterior lung images of 4 adult patients with cystic fibrosis following inhalation of an aerosol containing the radioisotope.

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Strategies for Infection Control in Cystic Fibrosis

Overview

Overview (cont)

Median FEV1 Percentage Predicted by Age

Pseudomonas aeruginosa

Key Elements of Infection Prevention and Controla,b*

Key Elements of Infection Prevention and Control (cont)

Key Elements of Infection Prevention and Control (cont)

Treatment Adherence Issues

Strategies to Improve Adherencea

New Tobramycin Delivery System

Eradicating P aeruginosa

Eradicating P aeruginosa (cont)

Long-term Medications for Lung Health in CFa,b

Long-term Medications for Lung Health in CFa,b (cont)

Patient Education and Adherence

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)